Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

Not Applicable

Not yet recruiting

• Conditions: Glucose; Metabolism; Isotope Labeling; Immune System and Related Disorders
• Interventions: Drug: 13C6-Glucose

• Registration Number: NCT06930976
• Lead Sponsor: Vanderbilt University Medical Center

Brief Summary

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-08
• Study First Submitted QC: 2025-04-08
• Last Update Submitted: 2025-04-08
• Study First Posted: 2025-04-16
• Last Update Posted: 2025-04-16
• Study Start: 2025-06-30
• Primary Completion: 2027-06-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Adults aged 18 or older

Exclusion Criteria

• Pregnant
• Prisoner or in police custody
• Uncontrolled hyperglycemia/diabetes
• Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
• Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
• Any reason which, in the opinion of the study investigator, adds additional risk to the participant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
13C6-Glucose	13C6-Glucose	10-25gm of 13C6-Glucose

Primary Outcome Measures

Name	Time	Method
13C6-glucose uptake in immune cells	Up to 4 hours	Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.

Trial Locations

Locations (1)

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States